Italian study tracks new combo therapy for advanced lung cancer in everyday practice

NCT ID NCT07190677

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This Italian study is collecting real-world data from 300 patients with advanced non-small cell lung cancer who are receiving a combination of nivolumab, ipilimumab, and chemotherapy as their first treatment. The goal is to see how long patients live and how long the cancer stays under control in everyday clinical settings, not just in clinical trials. Researchers are also tracking side effects and how well the treatment works in different patient groups.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
nivolumab plus ipilimumab plus chemotherapy
What this could lead to
If successful, this study could confirm that this drug combination works well in real-world patients, not just in controlled trials.
What could go wrong
This is an observational study, not a controlled experiment, so results may be less reliable. It also only includes patients in Italy, which may limit how well findings apply elsewhere.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER METASTATIC are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Fondazione IRCCS Policlinico San Matteo

    RECRUITING

    Pavia, Lombardy, 27100, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.